ஒன்றுபட்டது சிகிச்சை நிறுவனம் நாஸ்டாக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
United Therapeutics Corporation To Present At The 2021 Wedbush PacGrow Healthcare Virtual Conference
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
United Therapeutics Corporation To Report Second Quarter 2021 Financial Results Before The Market Opens On Wednesday, August 4, 2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
UNITED THERAPEUTICS : ANNOUNCES FDA ACCEPTANCE OF TYVASO DPI™ NEW DRUG APPLICATION FOR PRIORITY REVIEW (Form 8-K)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference
News provided by
Share this article
Share this article
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 25, 2021 /PRNewswire/ United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company s business during a fireside chat session at the Jefferies Virtual Healthcare Conference.
The session will take place virtually on Tuesday, June 1, 2021, from 3:30 p.m. to 3:55 p.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed at the same location for 90 days.
Message :
Required fields
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 5, 2021 /PRNewswire/ United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2021. Total revenue in the first quarter of 2021 grew 6% year over year to $379.1 million, compared to $356.3 million in the first quarter of 2020. 2021 is already a historic year for United Therapeutics, with the recent FDA approval and launch of Tyvaso for treatment of PH-ILD, submission of the Tyvaso DPI NDA, and the launch of our Remunity
® Pump for Remodulin
®, said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. In addition to these product launches and the potential Tyvaso DPI approval in December, we are progressing our late-stage pipeline with the commencement of the pivotal